William Creasman to Cisplatin
This is a "connection" page, showing publications William Creasman has written about Cisplatin.
Connection Strength
0.254
-
Phase II trial of cisplatin in advanced or recurrent cancer of the vagina: a Gynecologic Oncology Group Study. Gynecol Oncol. 1986 Jan; 23(1):101-4.
Score: 0.061
-
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 07; 390(10103):1654-1663.
Score: 0.034
-
Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Dec; 143(3):511-515.
Score: 0.032
-
Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study. Gynecol Oncol. 1995 Jun; 57(3):412-6.
Score: 0.029
-
A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 1990 Dec; 39(3):239-43.
Score: 0.021
-
Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 1989 Apr; 33(1):68-70.
Score: 0.019
-
Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol. 2007 Aug; 106(2):362-9.
Score: 0.017
-
Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: a Gynecologic Oncology Group Study. Am J Obstet Gynecol. 1985 Jun 15; 152(4):418-23.
Score: 0.015
-
A VP16-213- and cisplatin-containing regimen for treatment of refractory ovarian germ cell malignancies. Am J Obstet Gynecol. 1984 Dec 15; 150(8):927-31.
Score: 0.014
-
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1995 Jul; 13(7):1589-99.
Score: 0.007
-
A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer. 1986 May 01; 57(9):1725-30.
Score: 0.004